A12303 | Pages: NA | Sep 2022 | 306 Views | ||
Author(s) : Onkar Sumant | Tables: NA | Charts: NA |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Opioid Use Disorder Market
Request Now !Opioid is used for pain relief in patients with long-term pain symptoms. They often have a depressant effect on the central nervous system (CNS) and have the potential to cause euphoria. This is why the long-term use of opioids can make the person get dependent on them and become addicted; this dependence is known as opioid use disorder. In general, two types of patients are known to suffer from opioid use disorder, patients addicted to non-medical opioids and patients addicted to medical opioids. The most commonly abused opioids include oxycodone, hydrocodone, codeine, fentanyl, and morphine.
Market Scope and Structure Analysis
Report Metric | Details |
 Market Size Available for Years |  2020–2030 |
 Base Year Considered |  2020 |
 Forecast Period |  2021–2030 |
 Forecast Unit |  Value (USD) |
 Segments Covered |  Drug Type, Distribution Channel, and Region |
 Regions Covered |  North America, Europe, Asia-Pacific, and LAMEA |
 Companies Covered | Indivior PLC, Alkermes PLC, Teva Pharmaceutical Industries Ltd., MediciNova, Inc., Hikma Pharmaceuticals, Orexo AB, Camurus AB, and Omeros Corporation |
Â
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19.
However, with COVID-19 the supply chain of raw materials required to manufacture pharmaceutical products for opioid use disorder has been disrupted in many countries. In addition, the market growth of pharmaceuticals is declining, as manufacturers of drugs have slowed down their production due to the pandemic. This, in turn, is expected to have a significant impact on the opioid use disorder market.
Top Impacting Factors
The number of patients suffering from severe pain is increasing worldwide. This has led to an increased number of prescriptions for painkillers which often have opioids. Therefore, this factor is contributing to the growth of the opioid use disorder market.
Various forms of diseases such as cancer and cardiovascular diseases often cause severe and ongoing pain to the patients even after their treatments. Thus, alarming rise in the prevalence of such diseases is acting as a key driver of the global opioid use disorder market.
The number of people suffering from opioid addiction has significantly increased in recent years, which has led to the involvement of many government bodies and nongovernmental agencies, thus boosting the growth of the market.
However, one of the factors that can impede the growth of the opioid use disorder market is the side effects that may arise with the use of drugs in the treatment of opioid addiction.
Key Market Trends
The methadone segment of the opioid use disorder market is anticipated to register a low growth rate during the forecast period due to increasing number of generic product offerings and lack of new products in this segment.
The naltrexone segment of the market is expected to have a low market share owing to comparatively less number of product offerings.
In June 2020, Indegene, Inc. partnered with Titan Pharmaceuticals, Inc. in establishing a digital marketing program throughout the U.S. to increase their competence in the provision of their probuphine implant for opioid addiction patients.
In 2019, Dr. Reddy’s Laboratories announced the re-launch of its naloxone and buprenorphine sublingual film after the organization got a favorable ruling in its patent litigation.
Key Segments Covered
Segment | Subsegments |
 Drug Type |
|
 Distribution Channel |
|
 Region |
|
Â
Key Benefits of the Report
Questions Answered in the Opioid Use Disorder Report
Key Market Segments
Segments | Sub-segments |
---|---|
By Drug Type |
|
By Distribution Channel |
|
By Region |
|
Key Market Players
Loading Table Of Content...
Start reading.
This Report and over 13,000+ more Reports, Available with Avenue Library. T&C*.
10%
Discount
10%
Discount
15%
Discount
15%
Discount
Enterprise
License/PDF
20%
Discount
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers